Huons Biopharma Obtains Product Approval for 200 Units of Botulinum Toxin 'Liztox'
Equipped with a 3-Type Lineup of 50, 100, and 200 Units
[Asia Economy Reporter Seo So-jeong] Huons Biopharma, a subsidiary of Huons Global (CEO Kim Young-mok), announced on the 9th that it has obtained domestic approval from the Ministry of Food and Drug Safety for a new manufacturing unit of 200 units of the botulinum toxin 'Liztox' (export name HUTOX).
With this approval, Liztox now has a total of three lineups: 50 units, 100 units, and 200 units.
Huons Biopharma pursued approval for the new dosage based on the characteristics of botulinum toxin formulations, where the administered dose is determined according to the treatment site and scope. The 50-unit dosage is used mainly in the aesthetic field where relatively small doses are applied, while the 200-unit dosage is expected to enhance competitiveness in therapeutic areas such as post-stroke upper limb spasticity treatment and benign masseter hypertrophy, which are currently undergoing clinical trials.
Hot Picks Today
"Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- "500,000 Won Fine If You Don't Buy a Fire Extinguisher"... 'Fire Official Impersonation Phone Scams' on the Rise
- Despite Captivating the Nation for Over a Month... "Timmy" the Whale Ultimately Found Dead
- "If You Booked This Month, You Almost Lost Out... Why You Should Wait Until 'This Day' Before Paying for Flight Tickets"
Kim Young-mok, CEO of Huons Biopharma, said, "With the approval of the 200-unit dosage, we have secured all three units mainly used in medical practice," adding, "We expect Liztox's competitiveness in the domestic botulinum toxin market to be further strengthened."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
